Sanofi FR Stock Price, News & Analysis

Sanofi (NYSE:SNY) announced groundbreaking real-world study results for BEYFORTUS®, showing an 87% reduction in RSV disease cases across all care sites among healthy, term babies. The largest US real-world study demonstrated a remarkable 98% reduction in RSV hospitalizations compared to untreated infants.

The study, published in PEDIATRICS®, successfully met both co-primary endpoints. Beyond disease prevention, BEYFORTUS-treated infants who contracted RSV showed significantly fewer medical visits. The research included over 30,000 healthy, full-term babies, supporting previous findings from pivotal trials where BEYFORTUS showed 74.9% and 70.1% relative risk reductions in serious RSV disease.

Sanofi (NASDAQ:SNY) has launched its inaugural Healthy Futures Solution Fund, awarding over $1 million in grants to support Massachusetts-based nonprofits. The initiative aims to improve health equity and access to healthcare in historically undersupported communities.

The fund will support 14 nonprofit organizations including Boston Health Care for the Homeless, Boston Children's Hospital Trust, and Community Servings, focusing on addressing social drivers of health such as housing, food security, and behavioral health. The funding period extends through June 2026, after which organizations will submit impact reports detailing measurable outcomes.

Sanofi has agreed to acquire Blueprint Medicines for $129.00 per share in cash ($9.1B total), plus potential CVR payments worth up to $6 per share, bringing the total potential value to $9.5B. The acquisition centers on Blueprint's Ayvakit/Ayvakyt, the only approved medicine for advanced and indolent systemic mastocytosis (SM), a rare immunological disease. Ayvakit generated $479M in revenue in 2024 and showed 60% YoY growth in Q1 2025. The deal includes Blueprint's pipeline assets: elenestinib (Phase 2/3 for SM) and BLU-808 (early-stage KIT inhibitor). The transaction represents a 27% premium to Blueprint's closing price and is expected to close in Q3 2025. The acquisition will be immediately accretive to gross margin and accretive to business operating income and EPS after 2026.

Sanofi (SNY) has unveiled its new $130 million flagship US offices in Morristown, New Jersey, marking a significant expansion of its US presence. The 260,000-square-foot facility will accommodate nearly 2,000 employees and features state-of-the-art design elements focused on collaboration and innovation. The building is designed to achieve LEED Gold Certification and WELL Gold Building standards, with impressive sustainability metrics including 28% less energy usage and 24% reduced greenhouse gas emissions compared to standard offices. The facility offers modern amenities, including flexible workspaces, wellness rooms, a public restaurant, and New Jersey's largest outdoor terrace space. As part of its community commitment, Sanofi announced support for the Zufall Health Center and joined the Meal Recovery Coalition to address food insecurity in New Jersey.

Viz.ai has announced a multi-year partnership with Sanofi (SNY) and Regeneron (REGN) to develop and evaluate an AI-powered workflow solution for Chronic Obstructive Pulmonary Disease (COPD). The collaboration will focus on deploying the Viz COPD module, which uses electronic health record (EHR) data and artificial intelligence to improve detection and management of high-risk COPD patients.

The solution will be implemented across Viz.ai's network of over 1,700 hospitals and health systems, reaching more than 60,000 healthcare providers. COPD, affecting an estimated 392 million people globally and ranking as the fourth leading cause of death worldwide, remains underprioritized and undertreated. The AI-powered system will screen and triage patients using natural language processing, aligning with established clinical guidelines to identify high-risk individuals requiring follow-up care.

Sanofi (SNY) has announced plans to invest at least $20 billion in the United States through 2030, focusing on expanding research and development activities and domestic manufacturing capabilities. The investment aims to support the potential launch of several new first- or best-in-class medicines across various therapeutic areas. The company, which currently employs 13,000 people in the US, expects this investment to create numerous high-paying jobs across multiple states. The investment strategy includes a substantial increase in R&D spending and billions allocated to US manufacturing, both through direct investments in Sanofi facilities and partnerships with domestic manufacturers. This move is designed to strengthen the US supply chain and support hundreds of partner companies while advancing healthcare innovation.

Sanofi (SNY) has announced that Chrissy Teigen has joined as the new celebrity spokesperson for their Screen For Type 1 movement. The partnership, revealed on T1D Day, aims to promote early type 1 diabetes risk detection through screening.

Teigen's involvement stems from her personal experience with her son Miles, who was diagnosed with type 1 diabetes at age six in 2024 after an unexpected medical emergency. This reflects a common scenario, as approximately 64,000 Americans are diagnosed annually with type 1 diabetes, with up to 40% unaware of their condition until experiencing life-threatening complications.

The Screen For Type 1 initiative emphasizes that the disease can be detected through a single blood test that identifies diabetes-related autoantibodies before symptoms appear. While type 1 diabetes cannot be prevented, early detection can help families better prepare and plan for managing the condition.

Sanofi (SNY) has announced the immediate adoption of FDA-selected influenza strains for manufacturing its vaccine portfolio for the 2025-26 flu season in the US. The selected strains match those already in production by the company. Sanofi plans to begin shipping vaccines this summer to healthcare facilities for early season administration.

The announcement comes amid one of the worst flu seasons in decades, with CDC estimates showing 40 million illnesses, 520,000 hospitalizations, and 22,000 deaths through March 1. The company's 2025-26 US portfolio will include FLUZONE® High-Dose, FLUBLOK®, and FLUZONE® vaccines, covering patients from 6 months through 65+ years of age.

Sanofi and Orano Med have entered into an agreement to develop next-generation radioligand medicines for rare cancers. They will invest in a new entity under the Orano Med brand, focusing on discovery, design, and clinical development of radioligand therapies (RLTs) based on lead-212 (212Pb) alpha-emitting isotopes. This follows Sanofi's exclusive licensing agreement with Orano Med and RadioMedix for AlphaMedix™.

The collaboration aims to combine Sanofi's biopharma expertise with Orano's nuclear technology to advance cancer treatments. Sanofi will make an equity investment of €300 million, acquiring approximately 16% stake in the new entity valued at €1.9bn. The partnership is expected to accelerate the development of Orano Med's pipeline and leverage its capabilities in lead-212 based therapies.

Both companies are members of the Paris Saclay Cancer Cluster and aim to contribute to the France 2030 plan for oncology innovation. The agreement is subject to standard regulatory approvals.